REDUCING PATIENT ACCESSIBILITY BARRIERS IN THE CLINICAL SETTING AND THE VALUE OF LIVED EXPERIENCE
With
Hannah McPierzie, Disability Consultant & Advocate &
Chair, Deafblind West Australians &
Non-Executive Director, Deafness Forum Australia
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Perth | October 2025
Hannah McPierzie is a globally respected presenter, disability advocate, and educator who offers a unique perspective on disability and communication. She lives with Neurofibromatosis Type 2, a rare degenerative condition, and has two auditory brainstem implants. After 15 years teaching in the disability sector, Hannah acquired disability herself in 2020, when life-saving surgery left her deafblind.
Combining her professional expertise with lived experience, Hannah’s advocacy highlights the barriers people with disability face when navigating health systems, particularly in relation to communication access. She works with universities, hospitals, research institutes, private companies, and government agencies to build critical awareness of disability and to embed inclusive practices into policy and service design.
As Chairperson of Deafblind West Australians, Hannah has led initiatives that strengthen peer support and outreach for people with deafblindness. She is also a Non-Executive Director of Deafness Forum Australia, where she contributes to national advocacy on hearing loss. Her projects have included making advance care planning accessible for people with sensory loss, delivering community awareness training, and supporting the next generation of young leaders with disability.
Hannah is a keynote speaker at national and international conferences, where she champions the role of lived experience in health professions education and systemic reform. Her work consistently addresses the challenges of fragmented systems, inaccessible communication, and the need for genuine inclusion in decision-making. Based in Perth, Western Australia, Hannah continues to drive change that prioritises dignity, accessibility, and equity.
Source: Supplied
-
State of Private Hospitals sector in Australia
During Mr Roff’s working career at APHA he has represented the private hospitals sector to nine different Federal Health Ministers and eight Prime Ministers. He believes the government should take steps to regulate the health insurance industry to protect consumers and ensure that Australians have access to affordable and comprehensive healthcare services.
-
From paediatric nursing to leadership & private hospital general management
With over 20 years of experience in the Australian and international healthcare sectors, Georgia Banks is a dedicated and results-driven health professional with a proven track record in clinical, financial, human resources, and strategic management. Passionate about delivering high-quality patient care, Georgia possesses an authentic leadership style that fosters engagement, collaboration, and continuous improvement.
Currently serving as General Manager at Hobart Private Hospital within Healthscope, Georgia has been instrumental in driving operational excellence, enhancing patient experience, and supporting staff development. Her leadership has played a key role in aligning hospital services with strategic priorities while fostering a culture of accountability and innovation.
-
ICTD: Why negative results in clinical trials matter
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
